Contract Pharma

Contract Pharma

CONTRACT PHARMA stands out as the sole global publication dedicated to Bio/Pharma contract services, boasting a verified circulation of 20,026. This publication offers more in-depth editorial content on contract services and outsourcing than any other source. In 2013 alone, we featured over 700 pages of editorial content centered on outsourcing across our nine issues. CONTRACT PHARMA holds the top position in advertising market share for contract services and outsourcing providers within the Pharma and Biopharma sectors.

International, Trade/B2B
English
Magazine

Outlet metrics

Domain Authority
51
Ranking

Global

#582903

United States

#335607

Health/Biotechnology and Pharmaceuticals

#321

Traffic sources
Monthly visitors

Articles

  • 1 week ago | contractpharma.com | Tim Wright

    Contract development and manufacturing organizations (CDMOs) are no longer behind-the-scenes partners—they’re strategic players shaping the future of drug development. As the pharmaceutical industry navigates increasingly complex science, regulatory pressure, and global uncertainty, CDMOs are being called on to do more: scale fast, innovate constantly, and deliver quality without compromise.

  • 1 week ago | contractpharma.com | Tim Wright

    In this CEO Spotlight, Contract Pharma sits down with Nick Buschur, Chief Executive Officer of Woodstock Sterile Solutions, to discuss the company’s strategic transformation over the past year. Since taking the helm, Buschur has steered Woodstock with a sharp focus on operational excellence, innovation, and customer partnership—all anchored by deep expertise in blow-fill-seal technology.

  • 1 week ago | contractpharma.com | Tim Wright

    As pressures on global supply chains increase, pharmaceutical, biotech, and medical device companies are recognizing that supply chain resiliency depends not only on internal strengths, but on the importance of external partnerships that are fully aligned with their goals and expectations. For companies evaluating a Contract Packaging Organization (CPO), it’s no longer enough to assess capacity or capabilities.

  • 1 month ago | contractpharma.com | Kristin Brooks

    The World Obesity Federation’s Global Obesity Observatory estimates that 1 billion adults will have obesity by 2030, and more than half of the world’s population1 will live with overweight or obesity levels by 2035. As such, there has been tremendous focus and growth in obesity drug development, with Wegovy (semaglutide) and Zepbound (tirzepatide) becoming household names in recent years.

  • 1 month ago | contractpharma.com | Tim Wright

    Welcome to the April issue of Contract Pharma. This month’s edition highlights critical trends and challenges shaping the pharma manufacturing and development landscape, highlighting new regulatory requirements, advances in therapies, and shifts in manufacturing strategies. First, the pharmaceutical industry’s reliance on analytical testing has grown substantially, driven by increasing regulatory demands and the need for improved quality assurance.